Early/midstage study begins for OncoMed stem cell drug

09/19/2013 | RTT News

OncoMed Pharmaceuticals has begun a Phase Ib/II study to assess the efficacy of its anti-cancer stem cell candidate OMP-21M18, or demcizumab, with paclitaxel against platinum-resistant ovarian cancer, primary peritoneal cancer and fallopian tube cancer. The drug is also in early stage trials against pancreatic cancer and nonsmall-cell lung cancer.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN